CORE ONE LABS INC - CLABF STOCK NEWS

Core One Labs Inc. applauds Health Canada's amendment to the Special Access Programme (SAP), effective January 5, 2022, allowing physicians to request patient access to psychedelic treatments for serious conditions. This change marks a historic milestone in Canada's approach to mental health care, facilitating access to potentially life-saving medications for patients with treatment-resistant disorders. Additionally, Core One has lifted pooling restrictions on 5,814,000 common shares linked to its acquisition of New Path Laboratories and granted 2,144,000 Restricted Share Units under its plan.

Core One Labs has completed the acquisition of New Path Laboratories, enhancing its presence in the functional mushroom market. New Path specializes in natural health products and dietary supplements derived from functional mushrooms, utilizing a vertical integration model for low-cost production. The acquisition involves issuing 5,700,000 common shares, with a structured release over nine months. Joel Shacker, CEO, noted the acquisition's potential to generate sales revenue through expanded retail distribution channels, targeting the growing consumer demand for functional mushrooms.

Core One Labs Inc. (OTC: CLABD) applauds Seattle's city council for decriminalizing naturally occurring entheogenic drugs, including psilocybin, for personal and spiritual use. This makes Seattle the largest U.S. city to adopt such measures, joining nine others that have eased restrictions on psychedelics. The initiative aims to foster research and therapeutic use of these substances. Additionally, the company plans to issue 111,112 shares at $1.71 each to settle $190,000 in debt. The upcoming Annual General Meeting is scheduled for October 28, 2021, with a proxy submission deadline on October 26.

Core One Labs Inc. (OTC: CLABF) announced a Virtual Town Hall meeting on August 4, 2021, featuring Dr. Robert E.W. Hancock, Chairman and CEO of Vocan Biotechnologies. The event will present updates on the biosynthetic psilocybin production and allow live investor Q&A. CEO Joel Shacker emphasized the company's commitment to advancing psychedelic medicines through innovative delivery systems and psychotherapy. Core One aims to develop a patent-pending oral thin film technology for psilocybin while maintaining a patient database from medical clinics.

Core One Labs Inc. (CSE: COOL, OTC: CLABD) announced its pursuit of a listing on Nasdaq to enhance its investor profile and explore growth opportunities in the psychedelics sector. The company has completed an 8:1 share consolidation, resulting in 14,344,079 common shares outstanding, a step towards fulfilling Nasdaq's listing requirements. This move aims to attract institutional and retail investors while advancing its focus on psychedelic treatments for mental health. The listing is contingent upon meeting Nasdaq's regulatory requirements and obtaining approval.

Core One Labs Inc. (OTC: CLABF) has initiated the development of AKO001, a groundbreaking psychedelic drug formulation aimed at reducing neurological damage from ischemic strokes. This formulation combines DMT with a specific plant bioactive, which may help restore neural function post-stroke. A provisional patent has been filed in the U.S. for AKO001. Ischemic strokes are a leading cause of death and disability globally, affecting millions annually. The company is seeking research partners to advance this innovative treatment.

Core One Labs Inc. (CSE: COOL, OTC: CLABF) has announced that its subsidiary, Akome Biotech Ltd., is developing a next-generation psychedelic drug formulation, AKO001, aimed at mitigating neurological damage from ischemic strokes. The formulation combines DMT and a specific plant bioactive, showing potential in promoting neuronal recovery. A provisional patent application has been filed with the USPTO. Akome is currently seeking Contract Research Organizations to assist in development. Stroke is a leading cause of morbidity, with 17.9 million annual deaths globally.

Core One Labs Inc. (OTC: CLABF) announced plans for a share consolidation of eight pre-Consolidation shares for each post-Consolidation share as part of its preparation for a potential listing on Nasdaq. The current share count stands at 114,600,611. This strategic move aims to meet Nasdaq's regulatory requirements, including a minimum share price of $3.00. Core One believes this listing will enhance its visibility and enable further business opportunities in the U.S. psychedelic market. However, completion is contingent upon regulatory approvals and a final decision regarding the consolidation.

Core One Labs Inc. (OTC: CLABF) announces its subsidiary, Vocan Biotechnologies, is finalizing a provisional patent for its innovative biosynthetic psilocybin production system. This development aims to enhance efficiency and reduce costs in psilocybin production, addressing current market limitations. In partnership with the University of British Columbia, Vocan is focused on delivering consistent, high-quality psilocybin for medical research. The CEO emphasizes potential market leadership and profitability, given the high current market price of psilocybin, exceeding $7,000 USD per gram.